UY39754A - Composiciones y métodos para el tratamiento de la depresión - Google Patents
Composiciones y métodos para el tratamiento de la depresiónInfo
- Publication number
- UY39754A UY39754A UY0001039754A UY39754A UY39754A UY 39754 A UY39754 A UY 39754A UY 0001039754 A UY0001039754 A UY 0001039754A UY 39754 A UY39754 A UY 39754A UY 39754 A UY39754 A UY 39754A
- Authority
- UY
- Uruguay
- Prior art keywords
- patient
- treatment
- methods
- aticaprant
- modalities
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Treatment And Processing Of Natural Fur Or Leather (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/307,858 US11266627B1 (en) | 2021-05-04 | 2021-05-04 | Compositions and methods for the treatment of depression |
| US17/670,123 US12161622B2 (en) | 2021-05-04 | 2022-02-11 | Compositions and methods for the treatment of depression |
| US202263313792P | 2022-02-25 | 2022-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39754A true UY39754A (es) | 2022-11-30 |
Family
ID=81654924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039754A UY39754A (es) | 2021-05-04 | 2022-05-04 | Composiciones y métodos para el tratamiento de la depresión |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4333835A1 (https=) |
| JP (1) | JP2024516297A (https=) |
| KR (1) | KR20240004857A (https=) |
| AU (1) | AU2022268720A1 (https=) |
| BR (1) | BR112023023030A2 (https=) |
| CA (1) | CA3219079A1 (https=) |
| CL (1) | CL2023003259A1 (https=) |
| CO (1) | CO2023015571A2 (https=) |
| IL (1) | IL308221A (https=) |
| JO (1) | JOP20230276A1 (https=) |
| MX (1) | MX2023013040A (https=) |
| PE (1) | PE20241784A1 (https=) |
| PH (1) | PH12023552963A1 (https=) |
| TW (1) | TW202313003A (https=) |
| UY (1) | UY39754A (https=) |
| WO (1) | WO2022234457A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| AU2023231493A1 (en) * | 2022-03-07 | 2024-10-24 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| WO2024216046A1 (en) * | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating anhedonia |
| WO2024216061A1 (en) * | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating depression and anhedonia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
-
2022
- 2022-05-03 PH PH1/2023/552963A patent/PH12023552963A1/en unknown
- 2022-05-03 KR KR1020237041546A patent/KR20240004857A/ko active Pending
- 2022-05-03 PE PE2023003004A patent/PE20241784A1/es unknown
- 2022-05-03 TW TW111116720A patent/TW202313003A/zh unknown
- 2022-05-03 AU AU2022268720A patent/AU2022268720A1/en active Pending
- 2022-05-03 CA CA3219079A patent/CA3219079A1/en active Pending
- 2022-05-03 EP EP22723794.8A patent/EP4333835A1/en active Pending
- 2022-05-03 WO PCT/IB2022/054085 patent/WO2022234457A1/en not_active Ceased
- 2022-05-03 JP JP2023567994A patent/JP2024516297A/ja active Pending
- 2022-05-03 BR BR112023023030A patent/BR112023023030A2/pt unknown
- 2022-05-03 MX MX2023013040A patent/MX2023013040A/es unknown
- 2022-05-03 IL IL308221A patent/IL308221A/en unknown
- 2022-05-04 UY UY0001039754A patent/UY39754A/es unknown
-
2023
- 2023-11-02 JO JOJO/P/2023/0276A patent/JOP20230276A1/ar unknown
- 2023-11-02 CL CL2023003259A patent/CL2023003259A1/es unknown
- 2023-11-17 CO CONC2023/0015571A patent/CO2023015571A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023015571A2 (es) | 2023-11-30 |
| EP4333835A1 (en) | 2024-03-13 |
| IL308221A (en) | 2024-01-01 |
| CL2023003259A1 (es) | 2024-05-31 |
| WO2022234457A1 (en) | 2022-11-10 |
| PH12023552963A1 (en) | 2024-03-11 |
| PE20241784A1 (es) | 2024-09-06 |
| MX2023013040A (es) | 2024-01-05 |
| JP2024516297A (ja) | 2024-04-12 |
| KR20240004857A (ko) | 2024-01-11 |
| AU2022268720A1 (en) | 2023-12-21 |
| TW202313003A (zh) | 2023-04-01 |
| BR112023023030A2 (pt) | 2024-02-15 |
| CA3219079A1 (en) | 2022-11-10 |
| JOP20230276A1 (ar) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39754A (es) | Composiciones y métodos para el tratamiento de la depresión | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| UY38481A (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| ECSP18087352A (es) | Formulaciones de un inhibidor de lsd1 | |
| CL2022002592A1 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2024008886A (es) | Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2. | |
| CO5670327A2 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| DOP2020000160A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| CL2024001351A1 (es) | Composiciones y tratamientos con nirogacestat | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| MX2024005237A (es) | Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo. | |
| DOP2025000009A (es) | Inhibidores de acc novedosos | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX2024008618A (es) | Composiciones y métodos para el tratamiento de la depresión. | |
| MX2019004842A (es) | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. | |
| AR125762A1 (es) | Composiciones y métodos para el tratamiento de la depresión | |
| MX2025014866A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos | |
| AR045423A1 (es) | Combinaciones de analiticos y antidepresivos |